Oral Presentations |
Abstract and Session No. |
Title |
Presentation Date/Time |
Abstract 291 (Session 653) |
REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) |
Saturday, December 5, 2020 at 2:15 p.m. PST |
Abstract 271 (Session 612) |
Frequency and Prognostic Significance of Recurrent Gene Mutations in Pediatric B-ALL: Report from the DFCI ALL Consortium |
Saturday, December 5, 2020 at 3:15 p.m. PST |
Abstract 400 (Session 626) |
Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy |
Sunday, December 6, 2020 at 12:00 p.m. PST |
Abstract 476 (Session 627) |
Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era |
Sunday, December 6, 2020 at 2:00 p.m. PST |
Abstract 478 (Session 627) |
CNS Prophylaxis During Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions |
Sunday, December 6, 2020 at 2:30 p.m. PST |
Abstract 527 (Session 605) |
Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor |
Monday, December 7, 2020 at 7:45 a.m. PST |
Abstract 599 (Session 626) |
Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study |
Monday, December 7, 2020 at 9:30 a.m. PST |
Abstract 586 (Session 612) |
Pegaspargase Re-Challenge after Grade 2 Hypersensitivity Reaction in Childhood Acute Lymphoblastic Leukemia: Results from DFCI 16-001 |
Monday, December 7, 2020 at 10:00 a.m. PST |
Abstract 705 (Session 627) |
The Burkitt Lymphoma International Prognostic Index (BL-IPI) |
Monday, December 7, 2020 at 1:30 p.m. PST |
Abstract 706 (Session 627) |
Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis |
Monday, December 7, 2020 at 1:45 p.m. PST |
Poster Presentations |
Abstract and Session No. |
Title |
Presentation Date/Time |
Abstract 1102 (Session 621) |
Genomic Ancestry in B Cell Lymphoid Malignancies |
Saturday, December 5, 2020 at 7:00 a.m.-3:30 p.m. PST |
Abstract 1190 (Session 626) |
A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib As Frontline Therapy for Patients with MYC-Aberrant Lymphoid Malignancies: The Daciphor Regimen |
Saturday, December 5, 2020 at 7:00 a.m.-3:30 p.m. PST |
Abstract 1407 (Session 653) |
A Phase I Dose Escalation Study of PT-112 in Patients with Relapsed or Refractory Multiple Myeloma |
Saturday, December 5, 2020 at 7:00 a.m.-3:30 p.m. PST |
Abstract 2066 (Session 624) |
Prognostication for Advanced Stage Hodgkin Lymphoma (HL) in the Modern Era: A Project from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium |
Sunday, December 6, 2020 at 7:00 a.m.-3:30 p.m. PST |
Abstract 2046 (Session 623) |
Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study |
Sunday, December 6, 2020 at 7:00 a.m.-3:30 p.m. PST |
Abstract 2801 (Session 626) |
Baseline Biomarkers of T-Cell Function Correlate with Clinical Responses to Odronextamab (REGN1979), and Loss of CD20 Target Antigen Expression Identified As a Mechanism of Treatment Resistance |
Sunday, December 6, 2020 at 7:00 a.m.-3:30 p.m. PST |
Abstract 2503 (Session 902) |
Patient and Disease Factors Predict Risk of 1-Year Mortality Among Older Adults Who Receive Intensive Chemotherapy for Hodgkin Lymphoma (HL) |
Sunday, December 6, 2020 at 7:00 a.m.-3:30 p.m. PST |
Abstract 2478 (Session 901) |
Environmental Sars-Cov-2 Surface Testing: Low Incidence of Virus Positivity in Outpatient and Inpatient Hematology/Oncology Settings |
Sunday, December 6, 2020 at 7:00 a.m.-3:30 p.m. PST |
Abstract 2101 (Session 626) |
Final Report of Reduced Anthracycline Dose Intensity with the Addition of Dose Dense Rituximab in Children, Adolescents and Young Adults with De Novo Good Risk Mature B-Cell Non Hodgkin Lymphoma (B-NHL) |
Sunday, December 6, 2020 at 7:00 a.m.-3:30 p.m. PST |
Abstract 3297 (Session 721) |
Reduction of Clostridium Difficile Infection in an Academic Medical Center Blood and Marrow Transplant Population |
Monday, December 7, 2020 at 7:00 a.m.-3:30 p.m. PST |
Abstract 2978 (Session 624) |
Radiation-Based Approaches as an Alternative to Stem Cell Transplant for Relapsed/Refractory Classical Hodgkin Lymphoma: A Multicenter Retrospective Analysis |
Monday, December 7, 2020 at 7:00 a.m.-3:30 p.m. PST |
Abstract 3051 (Session 627) |
EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort |
Monday, December 7, 2020 at 7:00 a.m.-3:30 p.m. PST |
Share this article